{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-108859","form_type":"8-K","ticker":"ANNX","cik":"0001528115","company_name":"Annexon, Inc.","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.234188+00:00","generated_at":"2026-05-17T13:07:51.719573+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Annexon Q2 net loss $49.2M; tanruprubart MAA submission Q1 2026, ARCHER II topline H2 2026","bullets":["Net loss $49.2M ($0.34/share) in Q2 2025 vs $29.6M ($0.23) in Q2 2024; R&D $44.2M.","Cash and equivalents $227.0M as of June 30, 2025; runway into Q4 2026.","Tanruprubart MAA for GBS submission expected Q1 2026; FDA BLA discussions ongoing.","Vonaprument ARCHER II Phase 3 enrollment completed (659 patients); topline data H2 2026.","ANX1502 oral C1s inhibitor POC trial update in CAD anticipated by year-end 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-108859","json":"https://secwatch.observer/filing/0000950170-25-108859.json","markdown":"https://secwatch.observer/filing/0000950170-25-108859.md","text":"https://secwatch.observer/filing/0000950170-25-108859.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1528115/000095017025108859/0000950170-25-108859-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1528115/000095017025108859/annx-20250814.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:07:51.719573+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}